FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970596918> ?p ?o ?g. }

• W1970596918 endingPage "485" @default.
• W1970596918 startingPage "479" @default.
• W1970596918 abstract "Atherosclerotic peripheral artery disease (PAD) is common and results in limitations in quality of life and potential progression to limb loss. Options for therapy include medical therapy, supervised exercise, surgical revascularization, and, more recently, endovascular therapies to restore arterial perfusion to the limb. Endovascular revascularization has evolved over the past 2 decades, from percutaneous transluminal angioplasty (PTA) to self-expanding stents, atherectomy, laser angioplasty, and drug-eluting stents. Despite impressive technologic advances, PTA remains the standard of care at many institutions and is the recommended primary treatment modality for femoral-popliteal PAD according to current American College of Cardiology Foundation/American Heart Association guidelines. However, restenosis after PTA is common. Therefore, a significant clinical need remains for a device that is able to achieve more durable patency than PTA but does not require a permanent implant. Drug-coated balloons (DCBs) have the potential to address this need. Several randomized controlled clinical trials of PTA balloons coated with different formulations of paclitaxel have been conducted in Europe (N Engl J Med 2008;358:689-699) (Circulation 2008;118:1358-1365) (Circ Cardiovasc Interv 2012;5:831-840) (JACC Cardiovas Interv 2014;7:10-19) and demonstrated more durable efficacy than PTA with comparable safety. These studies were limited by small sample sizes and powered solely for an angiographic primary end point. The pivotal LEVANT 2 trial was designed in collaboration with the US Food and Drug Administration to demonstrate safety and efficacy in a large population and to obtain US Food and Drug Administration approval.A prospective, multicenter, single-blind trial comparing the Lutonix DCB (Bard Lutonix; New Hope, MN) versus PTA for treatment of femoropopliteal PAD (LEVANT 2) is the first US-based 2:1 randomized controlled trial of 476 patients with femoral-popliteal PAD designed to demonstrate superior efficacy and noninferior safety of a novel paclitaxel DCB compared with PTA. The primary efficacy end point is primary patency at 12 months. The primary safety end point is composite freedom at 12 months from perioperative death, index limb amputation, reintervention, and limb-related mortality. A series of important secondary end points include physical functioning, quality of life, revascularizations, and alternative measures of patency. To minimize bias potential for confounding variables, LEVANT 2 (1) excluded patients stented after predilation before randomization, (2) incorporated very stringent criteria for bailout stenting, (3) did not count bailout stenting as a target lesion revascularization or failure of any end point, (4) required a blinded clinician to perform clinical evaluations at follow-up, and (5) required clinical assessment before review of duplex ultrasound results.LEVANT 2 represents the first US-inclusive multicenter, randomized controlled trial to assess the safety and efficacy of a novel DCB compared with PTA as primary therapy for symptomatic PAD on the background of standard medical therapy." @default.
• W1970596918 created "2016-06-24" @default.
• W1970596918 creator A5003670547 @default.
• W1970596918 creator A5006083917 @default.
• W1970596918 creator A5016930592 @default.
• W1970596918 creator A5047252742 @default.
• W1970596918 creator A5065985671 @default.
• W1970596918 creator A5072997191 @default.
• W1970596918 creator A5086737942 @default.
• W1970596918 date "2015-04-01" @default.
• W1970596918 modified "2023-10-12" @default.
• W1970596918 title "Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial" @default.
• W1970596918 cites W122961614 @default.
• W1970596918 cites W1969838166 @default.
• W1970596918 cites W1994084703 @default.
• W1970596918 cites W2008850799 @default.
• W1970596918 cites W2012092298 @default.
• W1970596918 cites W2019734515 @default.
• W1970596918 cites W2025865331 @default.
• W1970596918 cites W2034354842 @default.
• W1970596918 cites W2102187172 @default.
• W1970596918 cites W2103000028 @default.
• W1970596918 cites W2108829308 @default.
• W1970596918 cites W2123302216 @default.
• W1970596918 cites W2125931002 @default.
• W1970596918 cites W2132880199 @default.
• W1970596918 cites W2144985796 @default.
• W1970596918 cites W2158595322 @default.
• W1970596918 cites W2168393911 @default.
• W1970596918 cites W2204863787 @default.
• W1970596918 cites W2572873578 @default.
• W1970596918 cites W2887033821 @default.
• W1970596918 cites W2887208783 @default.
• W1970596918 cites W4243656112 @default.
• W1970596918 cites W44924791 @default.
• W1970596918 doi "https://doi.org/10.1016/j.ahj.2014.11.016" @default.
• W1970596918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25819854" @default.
• W1970596918 hasPublicationYear "2015" @default.
• W1970596918 type Work @default.
• W1970596918 sameAs 1970596918 @default.
• W1970596918 citedByCount "16" @default.
• W1970596918 countsByYear W19705969182015 @default.
• W1970596918 countsByYear W19705969182016 @default.
• W1970596918 countsByYear W19705969182017 @default.
• W1970596918 countsByYear W19705969182018 @default.
• W1970596918 countsByYear W19705969182020 @default.
• W1970596918 countsByYear W19705969182021 @default.
• W1970596918 countsByYear W19705969182022 @default.
• W1970596918 countsByYear W19705969182023 @default.
• W1970596918 crossrefType "journal-article" @default.
• W1970596918 hasAuthorship W1970596918A5003670547 @default.
• W1970596918 hasAuthorship W1970596918A5006083917 @default.
• W1970596918 hasAuthorship W1970596918A5016930592 @default.
• W1970596918 hasAuthorship W1970596918A5047252742 @default.
• W1970596918 hasAuthorship W1970596918A5065985671 @default.
• W1970596918 hasAuthorship W1970596918A5072997191 @default.
• W1970596918 hasAuthorship W1970596918A5086737942 @default.
• W1970596918 hasConcept C126322002 @default.
• W1970596918 hasConcept C141071460 @default.
• W1970596918 hasConcept C168563851 @default.
• W1970596918 hasConcept C2777209855 @default.
• W1970596918 hasConcept C2778283817 @default.
• W1970596918 hasConcept C2778583881 @default.
• W1970596918 hasConcept C2778620186 @default.
• W1970596918 hasConcept C2779464278 @default.
• W1970596918 hasConcept C2780326628 @default.
• W1970596918 hasConcept C2780813298 @default.
• W1970596918 hasConcept C2908647359 @default.
• W1970596918 hasConcept C3018890749 @default.
• W1970596918 hasConcept C500558357 @default.
• W1970596918 hasConcept C535046627 @default.
• W1970596918 hasConcept C545542383 @default.
• W1970596918 hasConcept C71924100 @default.
• W1970596918 hasConcept C99454951 @default.
• W1970596918 hasConceptScore W1970596918C126322002 @default.
• W1970596918 hasConceptScore W1970596918C141071460 @default.
• W1970596918 hasConceptScore W1970596918C168563851 @default.
• W1970596918 hasConceptScore W1970596918C2777209855 @default.
• W1970596918 hasConceptScore W1970596918C2778283817 @default.
• W1970596918 hasConceptScore W1970596918C2778583881 @default.
• W1970596918 hasConceptScore W1970596918C2778620186 @default.
• W1970596918 hasConceptScore W1970596918C2779464278 @default.
• W1970596918 hasConceptScore W1970596918C2780326628 @default.
• W1970596918 hasConceptScore W1970596918C2780813298 @default.
• W1970596918 hasConceptScore W1970596918C2908647359 @default.
• W1970596918 hasConceptScore W1970596918C3018890749 @default.
• W1970596918 hasConceptScore W1970596918C500558357 @default.
• W1970596918 hasConceptScore W1970596918C535046627 @default.
• W1970596918 hasConceptScore W1970596918C545542383 @default.
• W1970596918 hasConceptScore W1970596918C71924100 @default.
• W1970596918 hasConceptScore W1970596918C99454951 @default.
• W1970596918 hasIssue "4" @default.
• W1970596918 hasLocation W19705969181 @default.
• W1970596918 hasLocation W19705969182 @default.
• W1970596918 hasOpenAccess W1970596918 @default.
• W1970596918 hasPrimaryLocation W19705969181 @default.
• W1970596918 hasRelatedWork W1557028984 @default.
• W1970596918 hasRelatedWork W1986135504 @default.

• next